Genhouse Bio
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $42M
Overview
Chinese biotech developing targeted oncology therapies focused on Ras-MAPK pathway and synthetic lethality mechanisms.
Oncology
Technology Platform
Platforms focused on targeting the Ras-MAPK signaling pathway and synthetic lethality mechanisms for oncology drug discovery.
Opportunities
Growing global interest in synthetic lethality approaches and Ras-MAPK pathway inhibitors presents significant market opportunities, particularly in precision oncology where targeted therapies command premium pricing.
Risk Factors
Clinical development risks for novel mechanisms, competition in oncology space, dependence on partnership success with Gilead for GH31, and typical biotech funding challenges.
Competitive Landscape
Competes with other companies developing Ras-MAPK pathway inhibitors (Amgen, Mirati) and synthetic lethality approaches (AstraZeneca, GlaxoSmithKline), but differentiates through specialized platforms and China-based innovation with global ambitions.